Traveling waves for nonlinear Schr\"odinger equations with nonzero conditions at infinity, II

We prove the existence of nontrivial finite energy traveling waves for a large class of nonlinear Schr\"odinger equations with nonzero conditions at infinity (includindg the Gross-Pitaevskii and the so-called "cubic-quintic" equations) in space dimension $N \geq 2$. We show that minimization of the energy at fixed momentum can be used whenever the associated nonlinear potential is nonnegative and it gives a set of orbitally stable traveling waves, while minimization of the action at constant kinetic energy can be used in all cases. We also explore the relationship between the families of traveling waves obtained by different methods and we prove a sharp nonexistence result for traveling waves with small energy.Comment: Final version, accepted for publication in the {\it Archive for Rational Mechanics and Analysis.} The final publication is available at Springer via http://dx.doi.org/10.1007/s00205-017-1131-

From image to technology: a multidisciplinary approach for improving the quality of organic bread.

This study is part of a research programme devoted to improving the quality of organic bread. It aims to identify and test prototypes of breads approved by consumers. This is achieved by analysing consumer representations and preferences and placing them within the framework of technological, sensory and nutritional dimensions of the products. The multidisciplinary approach implements an original qualitative approach that combines three consumer focus groups made up of both loyal and occasional consumers, and confrontation sessions with the programme scientific partners. Four prototypes of organic breads have thus been formalised and subsequently tested on a sample of 120 consumers from two sites (Angers and Strasbourg). From an operational point of view, proposals for organic breads approved by consumers are formulated. In terms of methodology, the contributions of a multidisciplinary study are discussed

A Preliminary Study of Image Analysis for Parasite Detection on Honey Bees

International Conference Image Analysis and Recognition (ICIAR 2018, Póvoa de Varzim, Portugal

Successful private–public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines

The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children. Responding to this mandate, five FP7 project calls were launched and 20 projects were granted. This paper aims to detail the funded projects and their preliminary results. Publicly available sources have been consulted and a descriptive analysis has been performed. Twenty Research Consortia including 246 partners in 29 European and non-European countries were created (involving 129 universities or public funded research organisations, 51 private companies with 40 SMEs, 7 patient associations). The funded projects investigate 24 medicines, covering 10 therapeutic areas in all paediatric age groups. In response to the Paediatric Regulation and to apply for a Paediatric Use Marketing Authorisation, 15 Paediatric Investigation Plans have been granted by the EMAPaediatric Committee, including 71 studies of whom 29 paediatric clinical trials, leading to a total of 7,300 children to be recruited in more than 380 investigational centres. Conclusion: Notwithstanding the EU contribution for each study is lower than similar publicly funded projects, and also considering the complexity of paediatric research, these projects are performing high-quality research and are progressing towards the increase of new paediatric medicines on the market. Private–public partnerships have been effectively implemented, providing a good example for future collaborative actions. Since these projects cover a limited number of offpatent drugs and many unmet therapeutic needs in paediatrics remain, it is crucial foreseeing new similar initiatives in forthcoming European funding programmes

Influence of Co layer thickness on the structural and magnetic properties of multilayers

International audienceThe correlated effects of the insertion of a Pt spacer between ferromagnetic and antiferromagnetic layers and of the variation of the Co layers thickness on the structural and magnetic properties of [ (Pt/Co tCo) 3 /Pt tPt /IrMn ] n multilayers have been studied. Samples with n = 1 and 7, t Co = 0.4 and 0.6 nm, t Pt = 0 and 0.4 nm have been investigated by tomographic atom probe and superconducting quantum interference device magnetometry. For spacer free samples (t Pt = 0), the structural investigation shows that when t Co = 0.4 nm, Mn and Ir atoms diffuse deeply in the (Pt/Co) multilayers. In contrast for t Co = 0.6 nm, the Mn and Ir diffusion is much reduced. Because Pt acts as a barrier against the Mn and Ir diffusion, this difference is less pronounced in samples with Pt insertion. The hysteresis loops shapes, the exchange bias fields and the saturation magnetization values were correlated with the structural properties of these samples and discussed, taking into account the susceptibility, exchange stiffness, and perpendicular magnetic anisotropy

Convergence of Ginzburg-Landau functionals in 3-d superconductivity

In this paper we consider the asymptotic behavior of the Ginzburg- Landau model for superconductivity in 3-d, in various energy regimes. We rigorously derive, through an analysis via {\Gamma}-convergence, a reduced model for the vortex density, and we deduce a curvature equation for the vortex lines. In a companion paper, we describe further applications to superconductivity and superfluidity, such as general expressions for the first critical magnetic field H_{c1}, and the critical angular velocity of rotating Bose-Einstein condensates.Comment: 45 page

An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.

Ethosuximide, the first-line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an innovative sugar-free, tasteless formulation convenient for pediatric use. This dual Phase-I study evaluated two granule formulations based on lipid multiparticulate (LMP) technology. Two panels of 6 healthy adult volunteers underwent a randomized, placebo-controlled, partly blinded, 3-way cross-over trial, comparing ethosuximide granules A or B with placebo granules and syrup at single 10 mg/kg doses. Corresponding plasma pharmacokinetic profiles of ethosuximide were compared, along with palatability, safety, and tolerability. The LMP granule A proved suboptimal due to bitterness and adherence to beaker walls, while the optimized granule B revealed excellent palatability, similar to placebo granules, and low adherence to glass. The relative bioavailability of granules A versus syrup, based on dose-normalized C <sub>max</sub> and AUC <sub>0-∞</sub> was 93.7% [90% CI: 76.3-115.1] and 96.1% [91.0-101.5], respectively. For granules B it was 87.6% [81.6-94.0] and 92.5% [88.5-96.6], respectively, with slightly delayed t <sub>max</sub> of 0.75 h [0.5-4.05] compared to syrup 0.5 h [0.3-0.8]. Tolerability visual analog scales revealed a trend for statistically non-significant improvement versus syrup at peak (30 min) for transient dizziness (both granules), fatigue (granules A), and anxiety (granules B). The innovative ethosuximide granule formulation B achieves a suitable profile for pediatric use, being sugar-free, tasteless, bioequivalent, and well-tolerated while enabling precise adjustment to body weight